Rybelsus

Active Ingredient(s): Semaglutide
FDA Approved: * September 20, 2019
Pharm Company: * NOVO NORDISK INC
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Rybelsus Overview

Semaglutide (trade names Rybelsus, Ozempic) is a medication for the treatment of type 2 diabetes.[1][2] Side effects include medullary thyroid cancer, kidney problems, diabetic retinopathy, allergic reactions, low blood sugar, and pancreatitis.[3] Semaglutide acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefi...

Read more Rybelsus Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Semaglutide

Recent Rybelsus Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Semaglutide
  • Solution: 2mg/1.5ml (1.34mg/ml)
  • Tablet: 14mg, 3mg, 7mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Rybelsus: (3 results)

Sorted by National Drug Code
  • 0169-4303 Rybelsus 3 mg Oral Tablet by Novo Nordisk
  • 0169-4307 Rybelsus 7 mg Oral Tablet by Novo Nordisk
  • 0169-4314 Rybelsus 14 mg Oral Tablet by Novo Nordisk

Other drugs which contain Semaglutide or a similar ingredient: (2 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 12 November 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA